Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Pantoloc M Pantoprazole magnesium Gastric acid secretion, reduction of List in a similar manner to other drugs in class Complete
Paxlovid nirmatrelvir/ritonavir Mild-to-moderate COVID-19, treatment Reimburse with clinical criteria and/or conditions Complete
pdp-levETIRAcetam Levetiracetam Epilepsy Reimburse with clinical criteria and/or conditions Complete
Pegasys RBV Peginterferon alfa-2a and Ribavirin Hepatitis C, chronic List in a similar manner to other drugs in class Complete
Pemazyre pemigatinib Cholangiocarcinoma Do not reimburse Complete
Pemazyre pemigatinib Cholangiocarcinoma Active
Perjeta pertuzumab Early stage breast cancer Do not reimburse Complete
Perjeta Herceptin Combo Pack Pertuzumab Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Perjeta or Perjeta-Herceptin Combo Pack Pertuzumab Neoadjuvant Breast Cancer Do not reimburse Complete
Perjeta-Herceptin Combo Pack Pertuzumab-Trastuzumab Combo Pack Early Breast Cancer Do not reimburse Complete